MET or NRAS amplification is an acquired resistance mechanism to the third-generation EGFR inhibitor naquotinib

Kiichiro Ninomiya(Okayama Shoka University), Katsuyuki Kiura(Okayama University Hospital)

Scientific Reports

January 25, 2018

10.1038/s41598-018-20326-z

Cited by 47

Related Papers

Trastuzumab Deruxtecan in Patients With <i>HER2</i>-Mutant Metastatic Non–Small-Cell Lung Cancer: Primary Results From the Randomized, Phase II DESTINY-Lung02 Trial

|Journal of Clinical Oncology|2023|293

Non–Small Cell Lung Cancer Cells Acquire Resistance to the ALK Inhibitor Alectinib by Activating Alternative Receptor Tyrosine Kinases

|Cancer Research|2016|128

Liposomal Delivery of MicroRNA-7–Expressing Plasmid Overcomes Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor-Resistance in Lung Cancer Cells

|Molecular Cancer Therapeutics|2011|126

VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene‐driven non‐small‐cell lung cancers

|Cancer Science|2021|54

<scp>JAK</scp>2‐related pathway induces acquired erlotinib resistance in lung cancer cells harboring an epidermal growth factor receptor‐activating mutation

|Cancer Science|2012|45